Updated:
AMBOSS
Founded in 2012 by Benedikt Hochkirchen, Siegfried Hümmer, and Navid Saleki, AMBOSS began as a digital study companion for German medical students — a...
AMBOSS
Founded in 2012 by Benedikt Hochkirchen, Siegfried Hümmer, and Navid Saleki, AMBOSS began as a digital study companion for German medical students — a high-yield question bank and cross-linked reference library. The founders were medical students themselves, building the tool they wanted. Within five years, adoption crossed 90% of Germany's medical schools, giving the company a near-monopoly on clinical-decision-support onboarding for a generation of German physicians. AMBOSS operates a hybrid education-clinical decision-support platform with revenue split across institutional licensing to hospitals and medical schools and individual subscriptions for students and residents. The core library covers 1,200+ clinical topics cross-linked to a differential-diagnosis engine and a USMLE/MCCQE question bank. Deployment spans North America and Europe, with the New York office opened to drive US hospital system adoption. In September 2021, AMBOSS raised $240 million in a round led by Eldridge and Mubadala Investment Company, with participation from Endeavor Catalyst and previous investors (per TechCrunch, 2021). The company had scaled to roughly 500 employees by the time of its $240 million raise, with offices in Cologne, Berlin, and New York. Total disclosed equity funding sits near $270 million. The firm operates a coding school scholarship program tied to its mission, but no separate family office or philanthropic foundation has been established. September 2021: The company raised $240 million in a round co-led by Eldridge and Mubadala, explicitly targeting expansion into US hospital systems and clinical-decision-support markets (per TechCrunch, September 2021). AMBOSS's structural differentiator is its bridge between two walled gardens — medical education and hospital clinical-decision-support — that are typically separate vendor categories. By training students on the AMBOSS platform during medical school and then converting them into hospital-system subscribers as residents and attendings, the company captures an unusual full-career-cycle relationship with physicians. This dual-channel model also creates a high-switching-cost dynamic: hospitals that adopt AMBOSS for clinical support reinforce adoption in the attached medical-education pipeline.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Cologne
Corporate office
Cologne, Germany
Additional offices
Berlin, Germany · New York, NY, United States
Principals
Benedikt Hochkirchen
Co-Founder & Managing Director
Siegfried Hümmer
Co-Founder & Managing Director
Navid Saleki
Co-Founder
Sector focus
Frequently asked questions
Who runs investment decisions at AMBOSS?
AMBOSS is a venture-funded operating company, not a family office or investment firm. Capital allocation decisions are made by the management team led by co-CEOs Benedikt Hochkirchen and Siegfried Hümmer, with board-level input from investors including Eldridge and Mubadala Investment Company.
How does AMBOSS relate to the Altss family-office universe?
AMBOSS does not operate as a family office and has not publicly disclosed a single-family capital vehicle for its founders. The connection to the Altss universe is its $240 million venture round co-led by Mubadala Investment Company, the Abu Dhabi sovereign wealth fund, and Eldridge, Todd Boehly's holding company — both of which are tracked in the LP and family-office ecosystem.
What is AMBOSS's known posture on co-investments alongside external GPs?
AMBOSS is not an institutional allocator and does not deploy into funds or participate in co-investments. It is an operating company that itself took venture capital investment. The firm has no publicly known vehicle for investing in external funds.
How does AMBOSS source its proprietary clinical content?
AMBOSS employs an in-house editorial team of over 100 physicians and medical editors who produce and continuously update its clinical library and question bank. This vertical-integration approach — owning content creation rather than aggregating third-party materials — is central to its quality-control model and differentiates it from aggregator platforms.
Which sectors does AMBOSS target beyond medical education?
AMBOSS's platform extends from medical education into clinical-decision-support at the point of care, positioning it at the intersection of education technology, digital health, and enterprise software for hospital systems. The company does not target consumer health, telehealth, or pharmaceutical services.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: